HealthMedia acquires MySelfHelp site

Share this article:
HealthMedia, a realtionship marketing firm focus ing on behavioral change, has acquired consumer health Web site MySelfHelp.com. Financial terms of the deal were not disclosed.

HealthMedia CEO Ted Dacko told reporters the “multimillion-dollar deal” represents “a huge revenue opportunity” that rounds out HealthMedia's product line.

With the acquisition, HealthMedia adds the site's interactive behavioral health programs for depression, insomnia and other behavioral health conditions to its repertoire of client offerings.
HealthMedia currently provides pharma companies with online patient compliance tools and generates online materials for health plans and large employers to initiate a dialogue with employees on consumer health issues such as healthy lifestyle and smoking cessation.

“We intend to offer MySelfHelp programs not only through the traditional behavioral healthcare and employee assistance program (EAP) channels, but to healthcare organizations and employers as part of our core health and disease management offering,” Dacko added.

HealthMedia's clients include Pfizer, GlaxoSmithKline, AstraZeneca, Eli Lilly, Takeda, Kaiser Permanente and Cleveland Clinic.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Judge blocks FDA bid to allow generic Precedex

Judge blocks FDA bid to allow generic Precedex

The US District Court for Maryland granted Hospira a temporary restraining order (TRO) against FDA, after the agency determined that potential generic competitors of the company's injectable sedation drug Precedex ...

GSK drug gets aplastic anemia indication

GSK drug gets aplastic anemia indication

Promacta was previously indicated for chronic immune thrombocytopenia.

Five things for Pharma Marketers to know: Wednesday, August 27

Five things for Pharma Marketers to know: Wednesday, ...

Allergan sets a shareholder voting date, Novo describes the types of acquisitions it will consider, and the AstraZeneca-Pfizer talks can now reopen.